Drugs News and Research

RSS

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Researchers determine whether mutations in the Omicron NTD influence its potential to stimulate myeloid cells and enhance inflammatory cytokine release.

22 May 2022

Neuroscientists pinpoint brain mechanism responsible for common type of age-related memory loss

Working with rats, neuroscientists at Johns Hopkins University have pinpointed a mechanism in the brain responsible for a common type of age-related memory loss.

20 May 2022

Montefiore Einstein Cancer Center partners with the Price Family Foundation to advance cancer equity

The National Cancer Institute-designated Montefiore Einstein Cancer Center (MECC) has partnered with the Price Family Foundation to fund eight research teams developing novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx.

20 May 2022

Research provides new insight into how Crimean-Congo hemorrhagic fever virus causes disease

Army scientists determined that the body's own natural immune response contributes to disease severity in mice infected with Crimean-Congo hemorrhagic fever virus (CCHFV), which causes a widespread tick-borne viral infection in humans.

20 May 2022

ANU research could lead to better treatment options for rare, deadly bacterial infection

New research from The Australian National University could lead to better treatment options for a rare but very lethal type of bacterial infection.

20 May 2022

Binary amplitude-only holograms with drug-elution capabilities

Holographic devices are used for security enhancement, entertainment, 3D display technologies and augmented reality but not limited to them.

20 May 2022

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

20 May 2022

Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.

20 May 2022

Exploring the possibility of whether surface ACE2 carried by extracellular vesicles can facilitate SARS-CoV-2 infection

Researchers explored whether surface ACE2 carried by EVs can facilitate the entry of SARS-CoV-2 into host cells.

20 May 2022

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

A new study has revealed that ATV006, which is a 5′-hydroxyl-isobutyryl prodrug, possesses extraordinary oral pharmaco-kinetic (PK) profiles in rats and cynomolgus monkeys and exhibited significant antiviral activity against ancestral SARS-COV-2 strain as well as VOCs.

20 May 2022

The link between androgens and COVID-19

A new paper examines the association between androgens and COVID-19, as revealed by the research carried out on this topic throughout the pandemic.

20 May 2022

Study demonstrates how the transcription factor C/EBPβ can positively influence fat storage

The chronic nutritional and metabolic disease of obesity is characterized by an excessive increase in body fat and its accumulation in tissues.

20 May 2022

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, instead of continuing with low-dose anticoagulant (apixaban).

20 May 2022

A step-by-step plan to create a digital twin of the human immune system

An article published May 20 in Nature Digital Medicine provides a step-by-step plan for an international effort to create a digital twin of the human immune system.

20 May 2022

Identification of long COVID patients through machine learning

Researchers developed a machine learning approach to identify patients with long coronavirus disease.

20 May 2022

New funding boost to combat antibiotic resistance

Antibiotics have saved countless lives since they were introduced in the 1940s, curing infections and making procedures like chemotherapy and surgeries safer. But their effectiveness is waning.

19 May 2022

Glaucoma treatment using smart contact lenses that release drugs

In a recent study published in the journal Nature Communications, researchers developed a wireless theranostic contact lens (WTCL) sensor for sensing intraocular pressure (IOP) in situ and delivering anti-glaucoma drugs on-demand.

19 May 2022

‘Sting’ protein’s response to clean up damaged brain cells may accelerate Parkinson’s disease progression

In studies with mouse and human tissue, as well as live mice, Johns Hopkins Medicine researchers report that a snag in the normal process of cleaning up broken DNA in brain cells may hasten the progression of Parkinson's disease.

19 May 2022

Molecular profiling of diseased joints could transform treatment for rheumatoid arthritis patients

New research from Queen Mary University of London, published in Nature Medicine, has shown that molecular profiling of the diseased joint tissue can significantly impact whether specific drug treatments will work to treat rheumatoid arthritis (RA) patients.

19 May 2022

Treating pediatric psychiatric disorders with psychotropic drugs reduces later substance use disorder risk

One half of psychiatric and substance use disorders start by the age of 18; three-quarters by age 24. While these are concerning statistics, a new study from Massachusetts General Hospital finds that treating psychiatric disorders with psychotropic medications in children and adolescents does not increase the risk of developing substance use, misuse, or substance use disorder (SUD).

19 May 2022

Drugs News and Research

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Neuroscientists pinpoint brain mechanism responsible for common type of age-related memory loss

Montefiore Einstein Cancer Center partners with the Price Family Foundation to advance cancer equity

Research provides new insight into how Crimean-Congo hemorrhagic fever virus causes disease

ANU research could lead to better treatment options for rare, deadly bacterial infection

Binary amplitude-only holograms with drug-elution capabilities

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Exploring the possibility of whether surface ACE2 carried by extracellular vesicles can facilitate SARS-CoV-2 infection

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

The link between androgens and COVID-19

Study demonstrates how the transcription factor C/EBPβ can positively influence fat storage

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

A step-by-step plan to create a digital twin of the human immune system

Identification of long COVID patients through machine learning

New funding boost to combat antibiotic resistance

Glaucoma treatment using smart contact lenses that release drugs

‘Sting’ protein’s response to clean up damaged brain cells may accelerate Parkinson’s disease progression

Molecular profiling of diseased joints could transform treatment for rheumatoid arthritis patients

Treating pediatric psychiatric disorders with psychotropic drugs reduces later substance use disorder risk

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News